

## REMARKS

In response to the restriction requirement dated October 8, 2008; the undersigned elects Group I, claims 1-4, directed to a salt of S,S-reboxitine. In response to the election of species, the succinate salt is chosen. This election is with traverse.

In view of this restriction requirement, the claims have been amended. Claim 1 is now directed to the succinate salt. Claims 2 and 3 were accordingly cancelled. Non-elected claims 8-12 were amended to make them dependent upon claim 1 so that they may be rejoined once claim 1 is found allowable.

New claims 14-19 have been added to the specification. All of these claims ultimately depend from claim 1. They are directed to crystalline forms of the succinate salt of S,S-reboxitine.

It is respectfully submitted that the claims are in condition for allowance. If any minor amendment would place the case in condition for allowance, the undersigned invites a phone call to discuss such changes at the number below.

Date: 11/6/08

Respectfully submitted,



J. Michael Dixon

Reg. No. 32,410

Attorney for Applicant

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
Tel.: (860)686-9018